Jacob Hooker

Jacob Hooker has held a variety of roles in the medical and research fields since 2007. From 2007 to 2009, they worked at Brookhaven National Laboratory as an Associate Scientist, Assistant Scientist, and Goldhaber Fellow. In 2009, Hooker began working at Massachusetts General Hospital as the Scientific Director of the Lurie Center for Autism, Phyllis and Jerome Lyle Rappaport MGH Research Scholar, Director of Radiochemistry at the Athinoula A. Martinos Center for Biomedical Imaging, and Associate Director of the PET Core. In the same year, Hooker began working at Harvard Medical School as a Professor of Radiology, Associate Professor of Radiology, and Assistant Professor. In 2010, Hooker joined the Massachusetts Institute of Technology (MIT) as a MIT linQ Catalyst Faculty. From 2017 to 2021, Hooker was the Co-Founder of Eikonizo Therapeutics and Sensorium Therapeutics, respectively. Additionally, Hooker was the Editor-in-Chief and Associate Editor of ACS Chemical Neuroscience at the American Chemical Society from 2013 to 2021. Lastly, Hooker has been a Scientific Advisor for Delix Therapeutics, Psy Therapeutics, Inc, and Fuzionaire Diagnostics since 2021, 2018, and 2020, respectively.

Jacob Hooker obtained their Bachelor's degree in Chemistry from North Carolina State University from 1998 to 2002. Jacob then went on to pursue their Ph.D. in Chemistry at the University of California, Berkeley from 2002 to 2007.